Back to Top
Go Back
Journal Photo for Cancer Biology & Therapy
Peer reviewed only Open Access

Cancer Biology & Therapy (CBT)

Publisher : Taylor & Francis
Cancer Biology & Therapy exchange of information Pharmacogenomics
e-ISSN 1555-8576
p-ISSN 1538-4047
Issue Frequency Continuously
Impact Factor 4.4
Est. Year 2002
Mobile 4402080520500
DOI YES
Language English
APC YES
Impact Factor Assignee google scholar
Email enquiries@taylorandfrancis.com

Journal Descriptions

Cancer Biology & Therapy is a high-profile international journal examining all aspects of the molecular basis of cancer, with translational relevance to diagnosis and therapy. The goal is to foster communication and the rapid exchange of information through timely publication of important advances within the field. Topics covered include: Existing and emerging technologies such as genome sequencing to increase understanding of genomic and proteomic alterations occurring within tumors; Tumor pathogenesis, development and progression; Drug-drug interactions; mechanisms of action for novel agents; combination chemotherapy; Pharmacogenomics, pharmacodynamics, and pharmacokinetic properties of anticancer agents; Anticancer chemotherapeutic agents, biological agents, immunomodulatory drugs, cell therapy and gene therapy.

Cancer Biology & Therapy (CBT) is :-

  • International, Peer-Reviewed, Open Access, Refereed, Cancer Biology & Therapy, exchange of information, Pharmacogenomics, pharmacodynamics, pharmacokinetic properties of anticancer, relevance to diagnosis and therapy, research, reviews, meeting reports, bedside-to-bench reports, letters to the editor , Online or Print , Continuously Journal

  • UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1538-4047, E-ISSN: 1555-8576, Established: 2002, Impact Factor: 4.4
  • Provides Crossref DOI
  • Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE

Indexing

Publications of CBT

Siqi Chen August, 2015
IL-15 has been actively investigated for its potential in tumor immunotherapy. To enhance the anti-tumor activity of IL-15, the novel PFC-1 construct was designed, which comprises the follow...
Fibroblast growth factors (FGFs) and their receptors (FGFRs) are important for signaling to maintain cancer stem-like cells (CSCs) in esophageal squamous cell carcinoma (ESCC). However, whic...
Jiang Zhou June, 2019
Patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer can benefit significantly from EGFR tyrosine-kinase inhibitors (TKIs) treatment, but almost every pati...
Rui Yang November, 2022
Radiation resistance poses a major clinical challenge in breast cancer (BC) treatment, but little is known about how long noncoding RNA (lncRNA) may regulate this phenomenon. Here, we report...
Huiyong Chen July, 2023
Cisplatin resistance is a major therapeutic challenge in non-small cell lung cancer (NSCLC). Herein, the regulatory role of long non-coding RNA (lncRNA) ITGB2-AS1 in regulating NSCLC cisplat...
Jose Andres August, 2022
The PI3K/Akt and Wnt/β-catenin pathways play an important role in the acquisition of the malignant phenotype in cancer. However, there are few data regarding the role of the interplay betwe...
Qingfei Zheng July, 2023
Recent evidence has shown that the human microbiome is associated with various diseases, including cancer. The salivary microbiome, fecal microbiome, and circulating microbial DNA in blood p...
Tong Liu May, 2024
Triple-negative breast Cancer (TNBC) is an aggressive subtype lacking estrogen, progesterone, and HER2 receptors. Known for limited targeted therapies, it poses challenges and requires perso...
Chen Wang May, 2024
Cervical cancer (CC) is a prevalent malignancy among women worldwide. This study was designed to investigate the role of METTL14 in sorafenib-induced ferroptosis in CC. METTL14 expression an...
Kevin K. May, 2024
Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific antibodies conta...